Lenvatinib?

What is Lenvatinib and how does it work?

Lenvatinib is an orally available kinase inhibitor with a broad spectrum of activity against various tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), and others [1]. It has been approved by the U.S. FDA for the treatment of various types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

How does Lenvatinib compare with other cancer treatments?

Lenvatinib has been shown to be effective in treating certain types of cancer, including those that have become resistant to other treatments. In a clinical trial, Lenvatinib demonstrated improved progression-free survival compared to everolimus in patients with advanced renal cell carcinoma [2]. Lenvatinib has also been shown to have a favorable safety profile compared to other tyrosine kinase inhibitors.

What side effects are associated with Lenvatinib?

The most common side effects of Lenvatinib include diarrhea, hypertension, fatigue, nausea, and weight loss [3]. Serious side effects can occur, including severe hypertension, bleeding, and heart problems. Patients taking Lenvatinib should have regular blood pressure checks and monitoring for signs of bleeding or heart problems.

When does the patent for Lenvatinib expire?

The patent for Lenvatinib is expected to expire in 2029 [4]. However, generic versions of the drug may become available earlier if manufacturers file for approval and receive approval from regulatory authorities.

Why are companies challenging the patent for Lenvatinib?

Eisai, the manufacturer of Lenvatinib, has faced challenges from other companies seeking to market generic versions of the drug [5]. These challenges have led to lawsuits and other disputes between companies seeking to bring affordable versions of Lenvatinib to market.

Sources:

[1] https://www.drugpatentwatch.com/drug/levatinib
[2] https://clinicaltrials.gov/ct2/show/NCT00584149
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203322s000lbl.pdf
[4] https://www.drugpatentwatch.com/patent/US-10314243-B2
[5] https://www.reuters.com/article/us-eisai-generic-levatinib-idUSKCN1S90Y7